High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The company sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.
A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.
Oura Inc. is pitching its U.S. initial public offering to investors, aiming for a fully diluted value of about $15.62 billion as it sizes up demand for consumer tech deals. The smart-ring maker plans to price next week, as markets...
Smart ring maker Oura is seeking a valuation of as much as $15.6 billion in an IPO that could test investor appetite for a new wave of fall listings.
Oura, a smart ring maker, said Monday it launched a US initial public offering of 50 million common
Oura is offering 50 million shares at $40 to $44 each, targeting a fully diluted valuation of $15.62 billion
On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.
Oura, the Finnish maker of smart health-tracking rings, disclosed plans on Monday to sell 50 million shares priced between $40 and $44 each in its initial public offering. The offering could raise as much as $2.2 billion and value the company at up to $14.1 billion based on its outstanding...
Investing.com -- Oura is seeking to offer 50 million shares priced between $40 and $44 each, the company disclosed in a Monday SEC filing. The smart ring maker plans to offer 13.5 million shares, while existing stockholders will sell 36.5 million shares.
Shares in the company fell more than 4% as its CEO laid out plans for new blockbuster drugs in the next few years.
Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports.
The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents.
Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.
Doctors are exploring whether weight-loss drugs could also treat conditions such as endometriosis and Crohn’s disease.
By Richa Naidu LONDON, Sept 16 (Reuters) - Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said,
Investing.com -- Berenberg analyst Kerry Holford upgraded Eli Lilly to buy, raising its price target to $1,400 in a note Tuesday, representing almost 25% upside, as it backs the drugmaker to extend its lead in the fast-growing obesity market.
Pre-Market Stock Futures: Futures are trading lower as we count down to the Federal Reserve meeting and a likely 25-basis-point increase in the Fed funds rate on Wednesday. The same suspects drove today’s selling, and although all the major indices finished the day lower, they all closed well off the lows printed earlier in the […]
As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply.
The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
Novo Nordisk is shortening its name as part of an effort to boost its appeal to consumers in the obesity drug market, where the Danish drugmaker...
Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook
Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis announced a failure of its heart disease drug, pelacarsen, to reduce the risk of cardiovascular events compared with a placebo. The failure, which sent U.S.-traded Novartis shares down 14%, also cast doubt on similar drugs, including Amgen’s investigational treatment olpasiran.
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
The maker of Mounjaro and Zepbound just signed its 13th deal of the year.
The drug giant added to its immunotherapy portfolio.
Eli Lilly Stock Slides as Pharma Giant Strikes $2.9 Billion Merida Deal
Lilly also announced that combining its inflammation treatment Taltz with Zepbound delivered lasting improvements in adults with psoriasis or psoriatic arthritis who were obese in two late trials.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
